Reveromycin A, the dominant analogue of a complex of spiroketals isolated from a Streptomyces sp., is an inhibitor of the mitogenic activity of EGF (epidermal growth factor). It is a G1 phase cell cycle inhibitor, selectively inhibiting IleRS (isoleucyl-tRNA synthetase). Reveromycin A displays antiproliferative behaviour against human cell lines KB and K562, as well as potent antifungal activity. More recently it has been shown to induce apoptosis in osteoclasts thus inhibiting bone resorption.
1. Reveromycin A, an agent for osteoporosis, inhibits bone resorption by inducing apoptosis specifically in osteoclasts. Woo J.T. et al. Proc. Natl. Acad. Sci. U.S.A. 2006, 103, 4729. 2. Reveromycin A inhibits osteolytic bone metastasis of small-cell lung cancer cells, SBC-5, through an antiosteoclastic activity. Muguruma H. et al. Clin. Cancer Res. 2005, 11, 8822. 3. Identification of Saccharomyces cerevisiae isoleucyl-tRNA synthetase as a target of the G1-specific inhibitor Reveromycin A. Miyamoto Y. et al. J. Biol. Chem. 2002, 277, 28810. 4. Reveromycins, new inhibitors of eukaryotic cell growth. II. Biological activities. Takahashi H. et al. J. Antibiot. 1992, 45, 1414.
See how others have used Reveromycin A (CAS 134615-37-5). Click on the entry to view the PubMed entry .
PMID: # 18840695 Yano, A. et al. 2008. Proc. Natl. Acad. Sci. U.S.A. 105: 15541-15546.